Recommended Articles
Fundraising

Healthleap Raises $38M to Expand AI That Flags Undiagnosed Conditions in Hospital Patients

By Angeled · October 8, 2026 · Fundraising
Healthleap Raises $38M to Expand AI That Flags Undiagnosed Conditions in Hospital Patients
Healthleap Raises $38M to Expand AI That Flags Undiagnosed Conditions in Hospital Patients

Healthleap, a clinical AI startup that reads hospital patient records to identify people at risk of undiagnosed illnesses, has raised $38 million in combined seed and Series A funding, TechCrunch reported exclusively on October 7, 2026. The company chose not to disclose its valuation.

The Deal

The $38 million breaks down into two rounds: an $8 million seed round co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The company intends to use the capital to expand its platform to cover additional medical conditions and to grow its engineering, sales, customer success, and product teams.

Landing Sequoia and First Round as co-leads on the seed round, then Hummingbird for the Series A, is a strong validation sequence — top-tier early-stage conviction followed by a European growth-stage specialist doubling down on the scale-up.

What the Company Does

Healthleap was founded in South Africa in 2022 by siblings Jemima Meyer and Josiah Meyer. The company's origin is unusually clinical: Jemima, a working dietitian, built an early tool called NutriLeap to help dietitians find and treat patients sooner after watching nutritional needs go unnoticed in understaffed hospital workflows. She brought in Josiah, her brother and a serial entrepreneur, to take that problem beyond what one dietitian could reach.

The company pivoted from its nutrition-tool origins into a broader clinical AI platform. Healthleap's software sits on top of hospital electronic health record systems, continuously analyzing clinician notes, lab results, vital signs, medications, and diagnoses for signs that someone needs a closer look. CEO Josiah Meyer told TechCrunch that "a patient's chart holds two kinds of data" — structured fields like labs and vitals, plus "the most telling signs" buried in clinicians' written notes, such as poor appetite, recent weight loss, muscle loss, and trouble swallowing.

The software does not diagnose patients. It assigns risk scores and routes them into existing clinical workflows so care teams can decide what happens next.

The platform currently screens for malnutrition and delirium and is deployed in more than 50 hospitals — up from just three hospital partners a year earlier. Programs for aspiration pneumonia, pressure injuries, and congestive heart failure readmission risk are undergoing further clinical validation, and Josiah has said the company wants to cover more than 40 major conditions and eventually expand into outpatient and home care.

Who's Backing It

Sequoia Capital, First Round Capital, and Hummingbird Ventures. The malnutrition gap the company targets is large: Healthleap estimates up to half of hospitalized patients may be at risk, yet fewer than 9% receive a diagnosis — a gap that means longer stays, worse outcomes, and millions in added costs.

Early clinical evidence supports the approach. A 2025 retrospective study at one Cedars-Sinai hospital evaluated 166,841 admissions and found Healthleap's model roughly doubled sensitivity for malnutrition detection versus the incumbent nurse-administered screening tool. The company also claims a case study at Penn Medicine's Hospital of the University of Pennsylvania showed meaningful financial impact from malnutrition screening, with shorter stays and additional reimbursement.

Why It Matters (For Founders and Investors)

Healthcare AI has a credibility problem: plenty of pilots, few deployments that survive contact with clinical workflows. Healthleap's growth from 3 to 50+ hospitals in a year is the metric that matters here — it suggests the product fits how hospitals actually buy and deploy software, integrating risk scores into existing workflows rather than demanding new ones.

For founders, the lesson is in the wedge. Healthleap didn't start by promising a general-purpose clinical AI platform; it started with one measurable condition (malnutrition) where it could compare results against dietitian assessments and discharge records, then expanded. In regulated, high-stakes markets, a narrow, verifiable wedge beats a broad, unprovable vision.

For investors, the company is a bet on the "safety net" thesis: hospitals are short-staffed, patients get missed, and software that catches what busy teams overlook has both clinical and financial value — shorter stays and more appropriate diagnoses translate directly into hospital economics. The planned expansion to 40+ conditions and outpatient care offers a large surface for growth, provided each new condition program clears clinical validation.

Angeled.com connects founders with investors.

Read Next